[go: up one dir, main page]

WO2006027693A3 - Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis - Google Patents

Tumor specific genes and variant RNAS and uses thereof as targets for cancer therapy and diagnosis Download PDF

Info

Publication number
WO2006027693A3
WO2006027693A3 PCT/IB2005/002934 IB2005002934W WO2006027693A3 WO 2006027693 A3 WO2006027693 A3 WO 2006027693A3 IB 2005002934 W IB2005002934 W IB 2005002934W WO 2006027693 A3 WO2006027693 A3 WO 2006027693A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnosis
targets
cancer therapy
specific genes
tumor specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002934
Other languages
French (fr)
Other versions
WO2006027693A2 (en
WO2006027693A8 (en
Inventor
Kevin Mcgowan
Vinayaka Kotraiah
Michael Brenner
Richard Einstein
Laurent Bracco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to EP05788127A priority Critical patent/EP1786906A2/en
Priority to US11/575,032 priority patent/US20080254031A1/en
Publication of WO2006027693A2 publication Critical patent/WO2006027693A2/en
Publication of WO2006027693A8 publication Critical patent/WO2006027693A8/en
Publication of WO2006027693A3 publication Critical patent/WO2006027693A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Genes and variant RNAs that are differentially expressed in human colon tumor tissues compared with normal colon tissue and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of colon cancer.
PCT/IB2005/002934 2004-09-09 2005-09-07 Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis Ceased WO2006027693A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05788127A EP1786906A2 (en) 2004-09-09 2005-09-07 Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
US11/575,032 US20080254031A1 (en) 2004-09-09 2005-09-07 Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60807604P 2004-09-09 2004-09-09
US60/608,076 2004-09-09

Publications (3)

Publication Number Publication Date
WO2006027693A2 WO2006027693A2 (en) 2006-03-16
WO2006027693A8 WO2006027693A8 (en) 2006-06-22
WO2006027693A3 true WO2006027693A3 (en) 2006-07-06

Family

ID=35464098

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002934 Ceased WO2006027693A2 (en) 2004-09-09 2005-09-07 Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis

Country Status (3)

Country Link
US (1) US20080254031A1 (en)
EP (1) EP1786906A2 (en)
WO (1) WO2006027693A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
DE102005022047A1 (en) * 2005-05-09 2006-11-30 Dade Behring Marburg Gmbh Binding partner of the placental growth factor, in particular antibodies directed against the placental growth factor, their production and use
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
WO2008153933A2 (en) * 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009015841A1 (en) * 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
DE102009031270A1 (en) * 2009-06-30 2011-01-05 Meiss, A. Ludwig, Prof. Dr. med. Thrombosis and osteoporosis prophylaxis
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
HRP20190044T1 (en) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. VEGF / DLL4 Binding AGENTS AND THEIR USES
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
MX382902B (en) 2014-10-31 2025-03-13 Oncomed Pharm Inc NOTH PATHWAY INHIBITOR IN COMBINATION WITH AN IMMUNOTHERAPEUTIC AGENT FOR USE IN THE TREATMENT OF CANCER.
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
WO2004061423A2 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6863887B1 (en) * 1998-03-30 2005-03-08 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094629A2 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
WO2004061423A2 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers

Also Published As

Publication number Publication date
WO2006027693A2 (en) 2006-03-16
EP1786906A2 (en) 2007-05-23
WO2006027693A8 (en) 2006-06-22
US20080254031A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2008003656A3 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
TNSN05300A1 (en) Treatment with anti-vegf antibodies
ZA200709780B (en) Anti-EGFR antibody therapy based on an increased copy number of the EGFR gene in tumor tissues
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
WO2006015263A3 (en) Lonidamine analogs
WO2004046342A3 (en) Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas
EP3064509A3 (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
WO2005065418A3 (en) Compositions and methods of use of targeting peptides for diagnosis and therapy
EP2433961A3 (en) Identification of tumor-associated antigens for diagnosis and therapy
WO2006027693A8 (en) Tumor specific genes and variant rnas and uses thereof as targets for cancer therapy and diagnosis
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO2006014999A3 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
WO2006031363A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2003245927A1 (en) Target genes for the diagnosis and treatment of cancer
WO2005051990A3 (en) Polynucleotides overexpressed in breast cancer cells, compositions and methods for the therapy and diagnosis of breast cancer
WO2009074253A3 (en) Clofarabine dietherphospholipid derivatives
WO2006037485A3 (en) Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
WO2007118077A3 (en) Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis
WO2007048097A3 (en) Anbrosteeone derivatives and method of use thereof
WO2003080800A3 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 11/2006 UNDER (71) REPLACE "EXONHIT THEROPEUTICS SA" BY "EXONHIT THERAPEUTICS SA"

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005788127

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWP Wipo information: published in national office

Ref document number: 2005788127

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11575032

Country of ref document: US